• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Exelixis Inc.

    3/20/23 4:39:35 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXEL alert in real time by email
    SC 13D 1 13d_exel.htm




    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC  20549

    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. )*

    Exelixis, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    30161Q104
    (Cusip Number)
     
    Hannah E. Dunn
    Farallon Capital Management, L.L.C.
    One Maritime Plaza, Suite 2100
    San Francisco, California 94111
    (415) 421-2132
    (Name, Address, and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    March 9, 2023
    (Date of Event which Requires Filing of this Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [   ].
    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Section 240.13d-7 for other parties to whom copies are to be sent.
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)
    Page 1 of 52 Pages
    Exhibit Index Found on Page 42



    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Partners, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    1,959,620
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    1,959,620
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,959,620
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.6%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN



    Page 2 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    2,450,882
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    2,450,882
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,450,882
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.8%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN



    Page 3 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners II, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    649,197
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    649,197
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    649,197
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN



    Page 4 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners III, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    332,586
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    332,586
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    332,586
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.1%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN



    Page 5 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Four Crossings Institutional Partners V, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    442,347
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    442,347
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    442,347
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.1%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN



    Page 6 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Offshore Investors II, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    4,059,527
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    4,059,527
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    4,059,527
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    1.3%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN



    Page 7 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital (AM) Investors, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    218,833
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    218,833
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    218,833
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.1%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN



    Page 8 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital F5 Master I, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    845,208
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    845,208
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    845,208
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.3%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN



    Page 9 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Healthcare Partners Master, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    12,507,800
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    12,507,800
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    12,507,800
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    3.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN



    Page 10 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Partners, L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    22,620,792
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    22,620,792
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    22,620,792
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.0%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO



    Page 11 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Institutional (GP) V, L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    442,347
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    442,347
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    442,347
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.1%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO



    Page 12 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon F5 (GP), L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    845,208
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    845,208
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    845,208
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.3%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO



    Page 13 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Healthcare Partners (GP), L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    12,507,800
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    12,507,800
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    12,507,800
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    3.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO



    Page 14 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Joshua J. Dapice
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 15 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Philip D. Dreyfuss
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 16 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Hannah E. Dunn
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 17 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Michael B. Fisch
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 18 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Richard B. Fried
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 19 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Varun N. Gehani
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 20 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Nicolas Giauque
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    France
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 21 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    David T. Kim
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 22 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Michael G. Linn
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 23 of 52 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Rajiv A. Patel
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 24 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Thomas G. Roberts, Jr.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 25 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Edric C. Saito
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 26 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    William Seybold
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 27 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Daniel S. Short
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 28 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Andrew J. M. Spokes
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 29 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    John R. Warren
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 30 of 52 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Mark C. Wehrly
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [ X ]
                                                                                                                                     (b) [   ]**
    ** The reporting persons making this filing hold an aggregate of 23,466,000 Shares (as defined in Item 1), representing 7.2% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    23,466,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    23,466,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    23,466,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN



    Page 31 of 52 Pages

    Item 1. Security and Issuer

    This statement relates to shares of common stock, par value $0.001 per share (the “Shares”), of Exelixis, Inc. (the “Company”).  The principal executive office of the Company is 1851 Harbor Bay Parkway, Alameda, California 94502.

    Item 2. 
    Identity and Background

    (a) This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the “Reporting Persons.”
    The Farallon Funds

    (i)
    Farallon Capital Partners, L.P., a California limited partnership (“FCP”), with respect to the Shares held by it;
    (ii)
    Farallon Capital Institutional Partners, L.P., a California limited partnership (“FCIP”), with respect to the Shares held by it;

    (iii)
    Farallon Capital Institutional Partners II, L.P., a California limited partnership (“FCIP II”), with respect to the Shares held by it;

    (iv)
    Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership (“FCIP III”), with respect to the Shares held by it;

    (v)
    Four Crossings Institutional Partners V, L.P., a Delaware limited partnership (“FCIP V”), with respect to the Shares held by it;

    (vi)
    Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership (“FCOI II”), with respect to the Shares held by it;

    (vii)
    Farallon Capital (AM) Investors, L.P., a Delaware limited partnership (“FCAMI”), with respect to the Shares held by it;

    (viii)
    Farallon Capital F5 Master I, L.P., a Cayman Islands exempted limited partnership (“F5MI”), with respect to the Shares held by it; and

    (ix)
    Farallon Healthcare Partners Master, L.P., a Cayman Islands exempted limited partnership (“FHPM”), with respect to the Shares held by it.

    FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, FCAMI, F5MI and FHPM are together referred to herein as the “Farallon Funds.”

    The Farallon General Partner

    (x)
    Farallon Partners, L.L.C., a Delaware limited liability company (the “Farallon General Partner”), which is (i) the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI, and (ii) the sole member of each of the FCIP V General Partner (as defined below) and the FHPM General Partner (as defined below) with respect to the Shares held by each of the Farallon Funds other than F5MI.


    Page 32 of 52 Pages

    The FCIP V General Partner

    (xi)
    Farallon Institutional (GP) V, L.L.C., a Delaware limited liability company (the “FCIP V General Partner”), which is the general partner of FCIP V, with respect to the Shares held by FCIP V.

    The F5MI General Partner

    (xii)
    Farallon F5 (GP), L.L.C., a Delaware limited liability company (the “F5MI General Partner”), which is the general partner of F5MI, with respect to the Shares held by F5MI.

    The FHPM General Partner

    (xiii)
    Farallon Healthcare Partners (GP), L.L.C., a Delaware limited liability company (the “FHPM General Partner”), which is the general partner of FHPM, with respect to the Shares held by FHPM.

    The Farallon Individual Reporting Persons
    (xiv)
    The following persons, each of whom is a managing member or senior managing member, as the case may be, of the Farallon General Partner, and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner, with respect to the Shares held by the Farallon Funds:  Joshua J. Dapice (“Dapice”); Philip D. Dreyfuss (“Dreyfuss”); Hannah E. Dunn (“Dunn”); Michael B. Fisch (“Fisch”); Richard B. Fried (“Fried”); Varun N. Gehani (“Gehani”); Nicolas Giauque (“Giauque”); David T. Kim (“Kim”); Michael G. Linn (“Linn”); Rajiv A. Patel (“Patel”); Thomas G. Roberts, Jr. (“Roberts”); Edric C. Saito (“Saito”); William Seybold (“Seybold”); Daniel S. Short (“Short”); Andrew J. M. Spokes (“Spokes”); John R. Warren (“Warren”); and Mark C. Wehrly (“Wehrly”).
    Dapice, Dreyfuss, Dunn, Fisch, Fried, Gehani, Giauque, Kim, Linn, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly are together referred to herein as the “Farallon Individual Reporting Persons.”
    (b)       The address of the principal business office of (i) each of the Farallon Funds is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111, and (ii) each of the FCIP V General Partner, the F5MI General Partner, the FHPM General Partner and the Farallon Individual Reporting Persons is set forth in Annex 1 hereto.
    (c)       The principal business of each of the Farallon Funds is that of a private investment entity engaging in the purchase and sale of investments for its own account. The principal business of the Farallon General Partner is to act as the general partner of investment partnerships, including FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI, and as the sole member of general partners of investment partnerships, including the FCIP V General Partner and the FHPM General Partner.  The principal business of each of the Farallon Individual Reporting Persons is set forth in Annex 1 hereto.

    Page 33 of 52 Pages

    (d)       None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e)       None of the Reporting Persons has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
     
    (f)       The jurisdiction of organization of each of the Farallon Funds, the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner is set forth above. Each of the Farallon Individual Reporting Persons, other than Giauque and Spokes, is a citizen of the United States.  Giauque is a citizen of France.  Spokes is a citizen of the United Kingdom.
     
    The other information required by Item 2 relating to the identity and background of the Reporting Persons is set forth in Annex 1 hereto.

    Item 3. Source and Amount of Funds or Other Consideration

    The approximate net investment cost for the Shares held by each of the Farallon Funds is set forth below:

    Entity
    Number of Shares Held
     
    Approx. Net Investment Cost
     
    FCP
    1,959,620
     
    $
    33,089,146
    FCIP
    2,450,882
     
    $
    41,318,860
    FCIP II
    649,197
     
    $
    11,063,831
    FCIP III
    332,586
     
    $
    5,682,040
    FCIP V
    442,347
     
    $
    7,514,391
    FCOI II
    4,059,527
    $
    68,589,662
           
    FCAMI
    218,833
     
    $
    3,725,536
    F5MI
    845,208
    $
    14,454,596
           
    FHPM
    12,507,800
    $
    224,597,482
           
       
    $
    410,035,544

    The consideration for such acquisitions was obtained from working capital and/or from borrowings pursuant to margin accounts maintained by the Farallon Funds with one or more brokers in the ordinary course of business.  Such margin accounts from time to time may have debit balances secured by Shares. Since other securities may be held in such margin accounts, it may not be possible to determine the amount, if any, of margin borrowings used to acquire the Shares.


    Page 34 of 52 Pages

     
    Item 4. Purpose of Transaction

    The disclosure set forth in Items 5 and 6 below is hereby incorporated by reference in this Item 4.

    The Reporting Persons believe that the securities of the Company are deeply undervalued and represent an attractive investment opportunity, and have invested in the Shares based on their belief in the long-term value of the Company.

    The Reporting Persons have communicated and intend to continue to communicate with the Company’s management and board of directors (the “Board”) about a variety of topics relating to the Company’s performance, business, operations, and governance.  Among other things, the Reporting Persons have conveyed to representatives of the Company the Reporting Persons’ concern about poor stock price performance, and their belief that the Company needs to refresh the Board, rationalize research and development efforts, return capital to stockholders (both through a significant share repurchase program and ongoing distributions), and improve investor communications.

    As part of the discussions described above, the Reporting Persons are in communication with the Board about its composition and potential candidates to serve as directors of the Company.

    The Reporting Persons intend to review their investment in the Company on a continuing basis. Depending upon various factors, including without limitation, the Company’s financial position and strategic direction, the outcome of any communications referenced above, overall market conditions, general economic and industry conditions, other investment opportunities available to the Reporting Persons, the liquidity requirements of the Reporting Persons, and the availability of securities of the Company at prices that would make the purchase or sale of such securities desirable, the Reporting Persons may endeavor to: (i) increase or decrease their position in the Company through, among other things, the purchase or sale of securities of the Company, including through transactions involving Shares and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of securities of the Company, in the open market or in private transactions, on such terms and at such times as the Reporting Persons may deem advisable; and/or (ii) enter into transactions that increase or decrease their economic exposure to the Shares without affecting the Reporting Persons’ beneficial ownership of the Shares, or adjust their exposure to the Shares in ways that would affect the Reporting Persons’ beneficial ownership of the Shares. 

    Except to the extent the foregoing may be deemed a plan or proposal, none of the Reporting Persons has any plans or proposals which relate to, or could result in, any of the matters referred to in subparagraphs (a) - (j) of Item 4 of Schedule 13D.  The Reporting Persons may, at any time and from time to time, (i) review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto and (ii) consider or propose one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D.

    Item 5. Interest in Securities of the Issuer
    The Farallon Funds

     
    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for each Farallon Fund is incorporated herein by reference for each such Farallon Fund.  The percentage amount set forth in Row 13 for all cover pages filed herewith is calculated based upon the 324,087,337 Shares outstanding as of January 30, 2023, as reported by the Company in its Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 7, 2023 (the “Company 10-K”).


    Page 35 of 52 Pages

     
    (c)
    The dates, number of Shares involved and the price per Share (excluding commissions) for all transactions in the Shares by the Farallon Funds in the past 60 days are set forth on Schedules A-I hereto and are incorporated herein by reference.  All of such transactions were open-market transactions.

     
    (d)
    The Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by the Farallon Funds other than F5MI.  The FCIP V General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FCIP V.  The F5MI General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by F5MI.  The FHPM General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FHPM.  Each of the Farallon Individual Reporting Persons is a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner.
     
     
    (e)
    Not applicable

    The Farallon General Partner


    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for the Farallon General Partner is incorporated herein by reference.

    (c) None.


    (d)
    The Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by the Farallon Funds other than F5MI.  Each of the Farallon Individual Reporting Persons is a managing member or senior managing member, as the case may be, of the Farallon General Partner.


    (e)
    Not applicable.

    The FCIP V General Partner


    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for the FCIP V General Partner is incorporated herein by reference.

    (c) None.


    (d)
    The FCIP V General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FCIP V.  Each of the Farallon Individual Reporting Persons is a manager or senior manager, as the case may be, of the FCIP V General Partner.


    (e)
    Not applicable.


    Page 36 of 52 Pages

    The F5MI General Partner


    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for the F5MI General Partner is incorporated herein by reference.

    (c) None.


    (d)
    The F5MI General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by F5MI.  Each of the Farallon Individual Reporting Persons is a manager or senior manager, as the case may be, of the F5MI General Partner.


    (e)
    Not applicable.

    The FHPM General Partner


    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for the FHPM General Partner is incorporated herein by reference.

    (c) None.


    (d)
    The FHPM General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FHPM.  Each of the Farallon Individual Reporting Persons is a manager or senior manager, as the case may be, of the FHPM General Partner.


    (e)
    Not applicable.

    The Farallon Individual Reporting Persons


    (a),(b) The information set forth in Rows 7 through 13 of the cover page hereto for each Farallon Individual Reporting Person is incorporated herein by reference for each such Farallon Individual Reporting Person.

    (c) None.


    (d)
    The Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by the Farallon Funds other than F5MI.  The FCIP V General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FCIP V.  The F5MI General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by F5MI.  The FHPM General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FHPM.  Each of the Farallon Individual Reporting Persons is a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner.


    (e)
    Not applicable.


    Page 37 of 52 Pages

    The Shares reported hereby for the Farallon Funds are owned directly by the Farallon Funds. The Farallon General Partner, as general partner of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of the FCIP V General Partner and the FHPM General Partner, may be deemed to be a beneficial owner of all such Shares owned by the Farallon Funds other than F5MI. The FCIP V General Partner, as general partner of FCIP V, may be deemed to be a beneficial owner of all such Shares owned by FCIP V. The F5MI General Partner, as general partner of F5MI, may be deemed to be a beneficial owner of all such Shares owned by F5MI.  The FHPM General Partner, as general partner of FHPM, may be deemed to be a beneficial owner of all such Shares owned by FHPM.  Each of the Farallon Individual Reporting Persons, as a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of all such Shares owned by the Farallon Funds.  Each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner, the FHPM General Partner and the Farallon Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares.

    The Reporting Persons have had discussions with certain third parties about the matters described in Item 4 above.

     The above-referenced third parties with whom the Reporting Persons have been in discussion include Caligan Partners LP, a Delaware limited partnership (“Caligan”), and Mr. David Johnson, who is the Managing Partner of Caligan.  Caligan serves indirectly as the investment manager to Caligan Partners Master Fund LP, a Cayman Islands limited partnership (the “Caligan Fund”), and certain managed accounts.  Based on information provided to them by Mr. Johnson, the Reporting Persons believe that the Caligan Fund and such managed accounts hold an aggregate of 850,000 Shares as of the date hereof, representing 0.26% of the Shares outstanding as reported in the Company 10-K.  Caligan, as the investment manager to the Caligan Fund and such managed accounts, and Mr. Johnson, as the Managing Partner of Caligan and the Managing Member of Caligan Partners GP LLC, the general partner of Caligan, each may be deemed a beneficial owner of such Shares held by the Caligan Fund and such managed accounts.

    As a result of the above discussions, the Reporting Persons may be deemed to have formed a “group” with Mr. Johnson and Caligan, within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, and Rule 13d-5(b)(1) thereunder.  The Shares reported herein as beneficially owned by the Reporting Persons do not include the Shares beneficially owned by Mr. Johnson and/or Caligan.  Mr. Johnson and Caligan have filed (or are expected to file) their own Schedule 13D with respect to their beneficial ownership of Shares.  Each of the Reporting Persons hereby disclaims any beneficial ownership of any Shares beneficially owned by Mr. Johnson and/or Caligan.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

    The disclosure set forth in Items 4 and 5 above is hereby incorporated by reference in this Item 6.

    Except as described above, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between such persons and any other person with respect to any securities of the Company, including but not limited to the transfer or voting of any securities of the Company, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.

    Item 7. Materials to be Filed as Exhibits

    There is filed herewith as Exhibit 1 a written agreement relating to the filing of joint acquisition statements as required by Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.


    Page 38 of 52 Pages


    SIGNATURES
    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
    Dated:  March 20, 2023
     
    /s/ John R. Warren
     
    FARALLON PARTNERS, L.L.C.,
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.,
     
    FARALLON CAPITAL OFFSHORE INVESTORS II, L.P. and
     
    FARALLON CAPITAL (AM) INVESTORS, L.P.
     
    By John R. Warren, Managing Member
       
     
    /s/ John R. Warren
     
    FARALLON INSTITUTIONAL (GP) V, L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FOUR CROSSINGS INSTITUTIONAL PARTNERS V, L.P.
     
    By John R. Warren, Manager
       
     
    /s/ John R. Warren
     
    FARALLON F5 (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL F5 MASTER I, L.P.
     
    By John R. Warren, Manager
       
     
    /s/ John R. Warren
     
    FARALLON HEALTHCARE PARTNERS (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON HEALTHCARE PARTNERS MASTER, L.P.
     
    By John R. Warren, Manager
       
     
    /s/ John R. Warren
     
    John R. Warren, individually and as attorney-in-fact for each of Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Andrew J. M. Spokes and Mark C. Wehrly

    The Powers of Attorney executed by each of Dapice, Dreyfuss, Dunn, Fisch, Fried, Gehani, Giauque, Kim, Linn, Patel, Roberts, Saito, Seybold, Short, Spokes and Wehrly authorizing Warren to sign and file this Schedule 13D on his or her behalf, which were filed as exhibits to the Schedule 13G filed with the SEC on January 31, 2023 by such Reporting Persons with respect to the Class A Ordinary Shares of ARYA Sciences Acquisition Corp IV, are hereby incorporated by reference.


    Page 39 of 52 Pages


    ANNEX 1
    Set forth below with respect to each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner is the following information: (a) name; (b) business address; (c) principal business; (d) state of organization; and (e) controlling persons.  Set forth below with respect to each managing member of the Farallon General Partner is the following information: (a) name; (b) business address; (c) principal occupation; and (d) citizenship.
     
     
    1.
    Farallon General Partner
     
     
    (a)
    Farallon Partners, L.L.C.
     
    (b)
    One Maritime Plaza, Suite 2100
    San Francisco, California 94111
     
    (c)
    Serves as the general partner of various investment partnerships and as the sole member of various general partners of investment partnerships
     
    (d)
    Delaware limited liability company
     
    (e)
    Managing Members: Andrew J.M. Spokes, Senior Managing Member; and Richard Bollini, Colby Clark, Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, Cameron Hillyer, David T. Kim, Michael G. Linn, Rajiv A. Patel, David A. Posner, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Matthew Trentini, John R. Warren and Mark C. Wehrly, Managing Members.
     
     
    2.
    FCIP V General Partner
     
     
    (a)
    Farallon Institutional (GP) V, L.L.C.
     
    (b)
    One Maritime Plaza, Suite 2100
    San Francisco, California 94111
     
    (c)
    Serves as the general partner of Four Crossings Institutional Partners V, L.P.
     
    (d)
    Delaware limited liability company
     
    (e)
    Managers: Andrew J.M. Spokes, Senior Manager; and Richard Bollini, Colby Clark, Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, Cameron Hillyer, David T. Kim, Michael G. Linn, Rajiv A. Patel, David A. Posner, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Matthew Trentini, John R. Warren and Mark C. Wehrly, Managers.
     
     
    3.
    F5MI General Partner
     
     
    (a)
    Farallon F5 (GP), L.L.C.
     
    (b)
    One Maritime Plaza, Suite 2100
    San Francisco, California 94111
     
    (c)
    Serves as the general partner of Farallon Capital F5 Master I, L.P.
     
    (d)
    Delaware limited liability company
     
    (e)
    Managers: Andrew J.M. Spokes, Senior Manager; and Richard Bollini, Colby Clark, Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, Cameron Hillyer, David T. Kim, Michael G. Linn, Rajiv A. Patel, David A. Posner, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Matthew Trentini, John R. Warren and Mark C. Wehrly, Managers.


    Page 40 of 52 Pages

     
    4.
    FHPM General Partner
     
     
    (a)
    Farallon Healthcare Partners (GP), L.L.C.
     
    (b)
    One Maritime Plaza, Suite 2100
    San Francisco, California 94111
     
    (c)
    Serves as the general partner of Farallon Healthcare Partners Master, L.P.
     
    (d)
    Delaware limited liability company
     
    (e)
    Managers: Andrew J.M. Spokes, Senior Manager; and Richard Bollini, Colby Clark, Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, Cameron Hillyer, David T. Kim, Michael G. Linn, Rajiv A. Patel, David A. Posner, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Matthew Trentini, John R. Warren and Mark C. Wehrly, Managers.

     
    5.
    Managing Members of the Farallon General Partner
     
    (a)
    Andrew J.M. Spokes, Senior Managing Member; and Richard Bollini, Colby Clark, Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, Cameron Hillyer, David T. Kim, Michael G. Linn, Rajiv A. Patel, David A. Posner, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Matthew Trentini, John R. Warren and Mark C. Wehrly, Managing Members.
     
    (b)
    c/o Farallon Partners, L.L.C.
    One Maritime Plaza, Suite 2100
    San Francisco, California 94111
     
    (c)
    The principal occupation of Andrew J.M. Spokes is serving as Senior Managing Member of the Farallon General Partner and Farallon Capital Management, L.L.C. The principal occupation of each other Managing Member of the Farallon General Partner is serving as a Managing Member of each of the Farallon General Partner and Farallon Capital Management, L.L.C.
     
    (d)
    Each of the Managing Members of the Farallon General Partner, other than Andrew J.M. Spokes, Nicolas Giauque and Cameron Hillyer, is a citizen of the United States. Mr. Spokes is a citizen of the United Kingdom.  Mr. Giauque is a citizen of France. Mr. Hillyer is a citizen of Australia.
     
    None of the Farallon General Partner and its Managing Members has any additional information to disclose with respect to Items 2-6 of this Schedule 13D that is not otherwise disclosed in this Schedule 13D.


    Page 41 of 52 Pages


    EXHIBIT INDEX

    1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k), dated March 20, 2023
     


    Page 42 of 52 Pages


    EXHIBIT 1
    to
    SCHEDULE 13D
     
    JOINT ACQUISITION STATEMENT
    PURSUANT TO SECTION 240.13d-1(k)
     
    The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.
     
    Dated: March 20, 2023
     
     
    /s/ John R. Warren
     
    FARALLON PARTNERS, L.L.C.,
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.,
     
    FARALLON CAPITAL OFFSHORE INVESTORS II, L.P. and
     
    FARALLON CAPITAL (AM) INVESTORS, L.P.
     
    By John R. Warren, Managing Member
       
     
    /s/ John R. Warren
     
    FARALLON INSTITUTIONAL (GP) V, L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FOUR CROSSINGS INSTITUTIONAL PARTNERS V, L.P.
     
    By John R. Warren, Manager
       
     
    /s/ John R. Warren
     
    FARALLON F5 (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL F5 MASTER I, L.P.
     
    By John R. Warren, Manager
       
     
    /s/ John R. Warren
     
    FARALLON HEALTHCARE PARTNERS (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON HEALTHCARE PARTNERS MASTER, L.P.
     
    By John R. Warren, Manager
       
     
    /s/ John R. Warren
     
    John R. Warren, individually and as attorney-in-fact for each of Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Andrew J. M. Spokes and Mark C. Wehrly


    Page 43 of 52 Pages


    SCHEDULE A

    FARALLON CAPITAL PARTNERS, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person during the past sixty days, inclusive of any transactions effected through 4:00 p.m., New York City time, on March 20, 2023. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    3/1/2023
    345,000 (P)
    $17.47
    3/9/2023
             116,500 (P)
    $16.641
    3/10/2023
     83,400 (P)
    $16.592
    3/10/2023
     67,000 (P)
    $16.563
    3/13/2023
             114,300 (P)
    $16.814
    3/14/2023
     31,200 (P)
    $17.245
    3/14/2023
     14,500 (P)
    $17.096
    3/15/2023
     2,200 (P)
    $17.487
    3/15/2023
     41,500 (P)
    $17.698
    3/15/2023
     2,800 (P)
    $17.409
    3/16/2023
    70,400 (P)
    $17.6010
    3/17/2023
    75,100 (P)
    $17.5911

    1 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.45 to $16.70 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within such range. The immediately preceding sentence applies to each footnote to this Schedule.
    2 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.42 to $16.68 inclusive.
    3 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.35 to $16.68 inclusive.
    4 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.59 to $16.95 inclusive.
    5 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.00 to $17.50 inclusive.
    6 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.05 to $17.15 inclusive.
    7 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.44 to $17.50 inclusive.
    8 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.32 to $17.85 inclusive.
    9 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.33 to $17.43 inclusive.
    10 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.39 to $17.74 inclusive.
    11 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.45 to $17.74 inclusive.

    Page 44 of 52 Pages


    SCHEDULE B

    FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person during the past sixty days, inclusive of any transactions effected through 4:00 p.m., New York City time, on March 20, 2023. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    3/1/2023
    419,300 (P)
    $17.47
    3/9/2023
    134,800 (P)
    $16.641
    3/10/2023
    96,800 (P)
    $16.592
    3/10/2023
    77,900 (P)
    $16.563
    3/13/2023
    133,800 (P)
    $16.814
    3/14/2023
    38,700 (P)
    $17.245
    3/14/2023
    18,000 (P)
    $17.096
    3/15/2023
     2,800 (P)
    $17.487
    3/15/2023
     52,200 (P)
    $17.698
    3/15/2023
     3,500 (P)
    $17.409
    3/16/2023
    88,600 (P)
    $17.6010
    3/17/2023
    91,800 (P)
    $17.5911

    1 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.45 to $16.70 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within such range. The immediately preceding sentence applies to each footnote to this Schedule.
    2 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.42 to $16.68 inclusive.
    3 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.35 to $16.68 inclusive.
    4 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.59 to $16.95 inclusive.
    5 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.00 to $17.50 inclusive.
    6 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.05 to $17.15 inclusive.
    7 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.44 to $17.50 inclusive.
    8 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.32 to $17.85 inclusive.
    9 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.33 to $17.43 inclusive.
    10 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.39 to $17.74 inclusive.
    11 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.45 to $17.74 inclusive.

    Page 45 of 52 Pages


    SCHEDULE C

    FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person during the past sixty days, inclusive of any transactions effected through 4:00 p.m., New York City time, on March 20, 2023. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    3/1/2023
    145,100 (P)
    $17.47
    3/9/2023
    44,300 (P)
    $16.641
    3/10/2023
    31,500 (P)
    $16.592
    3/10/2023
    25,400 (P)
    $16.563
    3/13/2023
    43,200 (P)
    $16.814
    3/14/2023
     12,500 (P)
    $17.245
    3/14/2023
     5,800 (P)
    $17.096
    3/15/2023
    900 (P)
    $17.487
    3/15/2023
      16,900 (P)
    $17.698
    3/15/2023
      1,100 (P)
    $17.409
    3/16/2023
    28,600 (P)
    $17.6010
    3/17/2023
    29,900 (P)
    $17.5911

    1 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.45 to $16.70 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within such range. The immediately preceding sentence applies to each footnote to this Schedule.
    2 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.42 to $16.68 inclusive.
    3 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.35 to $16.68 inclusive.
    4 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.59 to $16.95 inclusive.
    5 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.00 to $17.50 inclusive.
    6 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.05 to $17.15 inclusive.
    7 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.44 to $17.50 inclusive.
    8 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.32 to $17.85 inclusive.
    9 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.33 to $17.43 inclusive.
    10 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.39 to $17.74 inclusive.
    11 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.45 to $17.74 inclusive.

    Page 46 of 52 Pages


    SCHEDULE D

    FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person during the past sixty days, inclusive of any transactions effected through 4:00 p.m., New York City time, on March 20, 2023. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    3/1/2023
    78,400 (P)
    $17.47
    3/9/2023
    23,300 (P)
    $16.641
    3/10/2023
    16,600 (P)
    $16.592
    3/10/2023
    13,300 (P)
    $16.563
    3/13/2023
    22,700 (P)
    $16.814
    3/14/2023
      6,600 (P)
    $17.245
    3/14/2023
    3,100 (P)
    $17.096
    3/15/2023
    500 (P)
    $17.487
    3/15/2023
    8,865 (P)
    $17.698
    3/15/2023
      600 (P)
    $17.409
    3/16/2023
    15,000 (P)
    $17.6010
    3/17/2023
    15,700 (P)
    $17.5911

    1 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.45 to $16.70 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within such range. The immediately preceding sentence applies to each footnote to this Schedule.
    2 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.42 to $16.68 inclusive.
    3 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.35 to $16.68 inclusive.
    4 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.59 to $16.95 inclusive.
    5 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.00 to $17.50 inclusive.
    6 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.05 to $17.15 inclusive.
    7 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.44 to $17.50 inclusive.
    8 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.32 to $17.85 inclusive.
    9 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.33 to $17.43 inclusive.
    10 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.39 to $17.74 inclusive.
    11 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.45 to $17.74 inclusive.

    Page 47 of 52 Pages


    SCHEDULE E

    FOUR CROSSINGS INSTITUTIONAL PARTNERS V, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person during the past sixty days, inclusive of any transactions effected through 4:00 p.m., New York City time, on March 20, 2023. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    3/1/2023
    96,100 (P)
    $17.47
    3/9/2023
    27,800 (P)
    $16.641
    3/10/2023
     19,900 (P)
    $16.592
    3/10/2023
     16,000 (P)
    $16.563
    3/13/2023
    27,400 (P)
    $16.814
    3/14/2023
     7,900 (P)
    $17.245
    3/14/2023
     3,700 (P)
    $17.096
    3/15/2023
    600 (P)
    $17.487
    3/15/2023
    10,800 (P)
    $17.698
    3/15/2023
      700 (P)
    $17.409
    3/16/2023
    18,051 (P)
    $17.6010
    3/17/2023
    18,900 (P)
    $17.5911

    1 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.45 to $16.70 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within such range. The immediately preceding sentence applies to each footnote to this Schedule.
    2 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.42 to $16.68 inclusive.
    3 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.35 to $16.68 inclusive.
    4 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.59 to $16.95 inclusive.
    5 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.00 to $17.50 inclusive.
    6 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.05 to $17.15 inclusive.
    7 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.44 to $17.50 inclusive.
    8 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.32 to $17.85 inclusive.
    9 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.33 to $17.43 inclusive.
    10 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.39 to $17.74 inclusive.
    11 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.45 to $17.74 inclusive.

    Page 48 of 52 Pages


    SCHEDULE F

    FARALLON CAPITAL OFFSHORE INVESTORS II, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person during the past sixty days, inclusive of any transactions effected through 4:00 p.m., New York City time, on March 20, 2023. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    3/1/2023
    631,100 (P)
    $17.47
    3/9/2023
    216,700 (P)
    $16.641
    3/10/2023
    156,900 (P)
    $16.592
    3/10/2023
    126,100 (P)
    $16.563
    3/13/2023
    218,500 (P)
    $16.814
    3/14/2023
     60,200 (P)
    $17.245
    3/14/2023
     28,000 (P)
    $17.096
    3/15/2023
     4,200 (P)
    $17.487
    3/15/2023
     79,900 (P)
    $17.698
    3/15/2023
     5,400 (P)
    $17.409
    3/16/2023
    134,900 (P)
    $17.6010
    3/17/2023
    144,800 (P)
    $17.5911

    1 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.45 to $16.70 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within such range. The immediately preceding sentence applies to each footnote to this Schedule.
    2 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.42 to $16.68 inclusive.
    3 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.35 to $16.68 inclusive.
    4 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.59 to $16.95 inclusive.
    5 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.00 to $17.50 inclusive.
    6 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.05 to $17.15 inclusive.
    7 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.44 to $17.50 inclusive.
    8 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.32 to $17.85 inclusive.
    9 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.33 to $17.43 inclusive.
    10 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.39 to $17.74 inclusive.
    11 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.45 to $17.74 inclusive.

    Page 49 of 52 Pages


    SCHEDULE G

    FARALLON CAPITAL (AM) INVESTORS, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person during the past sixty days, inclusive of any transactions effected through 4:00 p.m., New York City time, on March 20, 2023. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    3/1/2023
    43,600 (P)
    $17.47
    3/9/2023
    12,900 (P)
    $16.641
    3/10/2023
    9,293 (P)
    $16.592
    3/10/2023
    7,400 (P)
    $16.563
    3/13/2023
    12,700 (P)
    $16.814
    3/14/2023
    3,500 (P)
    $17.245
    3/14/2023
    1,600 (P)
    $17.096
    3/15/2023
    200 (P)
    $17.487
    3/15/2023
     4,700 (P)
    $17.698
    3/15/2023
     300 (P)
    $17.409
    3/16/2023
    7,800 (P)
    $17.6010
    3/17/2023
    8,399 (P)
    $17.5911

    1 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.45 to $16.70 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within such range. The immediately preceding sentence applies to each footnote to this Schedule.
    2 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.42 to $16.68 inclusive.
    3 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.35 to $16.68 inclusive.
    4 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.59 to $16.95 inclusive.
    5 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.00 to $17.50 inclusive.
    6 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.05 to $17.15 inclusive.
    7 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.44 to $17.50 inclusive.
    8 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.32 to $17.85 inclusive.
    9 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.33 to $17.43 inclusive.
    10 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.39 to $17.74 inclusive.
    11 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.45 to $17.74 inclusive.

    Page 50 of 52 Pages


    SCHEDULE H

    FARALLON CAPITAL F5 MASTER, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person during the past sixty days, inclusive of any transactions effected through 4:00 p.m., New York City time, on March 20, 2023. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    3/1/2023
    177,800 (P)
    $17.47
    3/9/2023
    53,700 (P)
    $16.641
    3/10/2023
    38,700 (P)
    $16.592
    3/10/2023
    31,200 (P)
    $16.563
    3/13/2023
    53,729 (P)
    $16.814
    3/14/2023
    15,000 (P)
    $17.245
    3/14/2023
    7,000 (P)
    $17.096
    3/15/2023
    1,100 (P)
    $17.487
    3/15/2023
    19,900 (P)
    $17.698
    3/15/2023
     1,400 (P)
    $17.409
    3/16/2023
    33,400 (P)
    $17.6010
    3/17/2023
    35,600 (P)
    $17.5911

    1 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.45 to $16.70 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within such range. The immediately preceding sentence applies to each footnote to this Schedule.
    2 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.42 to $16.68 inclusive.
    3 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.35 to $16.68 inclusive.
    4 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.59 to $16.95 inclusive.
    5 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.00 to $17.50 inclusive.
    6 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.05 to $17.15 inclusive.
    7 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.44 to $17.50 inclusive.
    8 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.32 to $17.85 inclusive.
    9 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.33 to $17.43 inclusive.
    10 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.39 to $17.74 inclusive.
    11 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.45 to $17.74 inclusive.

    Page 51 of 52 Pages


    SCHEDULE I

    FARALLON HEALTHCARE PARTNERS MASTER, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person during the past sixty days, inclusive of any transactions effected through 4:00 p.m., New York City time, on March 20, 2023. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    3/1/2023
    2,539,978 (P)
    $17.47
    3/9/2023
    870,000 (P)
    $16.641
    3/10/2023
    625,616 (P)
    $16.592
    3/10/2023
    503,164 (P)
    $16.563
    3/13/2023
    864,931 (P)
    $16.814
    3/14/2023
    242,471 (P)
    $17.245
    3/14/2023
    112,796 (P)
    $17.096
    3/15/2023
    17,188 (P)
    $17.487
    3/15/2023
    323,993 (P)
    $17.698
    3/15/2023
    22,100 (P)
    $17.409
    3/16/2023
    547,903 (P)
    $17.6010
    3/17/2023
    580,274 (P)
    $17.5911

    1 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.45 to $16.70 inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within such range. The immediately preceding sentence applies to each footnote to this Schedule.
    2 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.42 to $16.68 inclusive.
    3 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.35 to $16.68 inclusive.
    4 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $16.59 to $16.95 inclusive.
    5 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.00 to $17.50 inclusive.
    6 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.05 to $17.15 inclusive.
    7 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.44 to $17.50 inclusive.
    8 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.32 to $17.85 inclusive.
    9 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.33 to $17.43 inclusive.
    10 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.39 to $17.74 inclusive.
    11 The purchase price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $17.45 to $17.74 inclusive.

    Page 52 of 52 Pages
    Get the next $EXEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXEL

    DatePrice TargetRatingAnalyst
    2/24/2025$36.00Overweight → Equal Weight
    Wells Fargo
    1/27/2025$30.00 → $40.00Equal-Weight → Overweight
    Morgan Stanley
    1/24/2025Outperform → Perform
    Oppenheimer
    12/20/2024$36.00 → $40.00Outperform → Market Perform
    BMO Capital Markets
    12/17/2024$35.00 → $39.00Buy → Neutral
    BofA Securities
    10/16/2024$30.00 → $34.00Outperform
    RBC Capital Mkts
    9/19/2024$30.00Neutral
    UBS
    4/11/2024$25.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $EXEL
    SEC Filings

    See more
    • SEC Form 144 filed by Exelixis Inc.

      144 - EXELIXIS, INC. (0000939767) (Subject)

      5/20/25 5:23:50 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Exelixis Inc.

      144 - EXELIXIS, INC. (0000939767) (Subject)

      5/15/25 4:05:42 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Exelixis Inc.

      10-Q - EXELIXIS, INC. (0000939767) (Filer)

      5/13/25 4:14:27 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exelixis downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Exelixis from Overweight to Equal Weight and set a new price target of $36.00

      2/24/25 7:08:46 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Exelixis from Equal-Weight to Overweight and set a new price target of $40.00 from $30.00 previously

      1/27/25 7:40:23 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis downgraded by Oppenheimer

      Oppenheimer downgraded Exelixis from Outperform to Perform

      1/24/25 7:28:21 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/30/24 7:50:14 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      2/22/24 5:08:50 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Johnson David Edward sold $2,602,038 worth of shares (120,409 units at $21.61) and bought $2,602,038 worth of shares (120,409 units at $21.61) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      11/29/23 4:30:29 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Leadership Updates

    Live Leadership Updates

    See more
    • ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

      TORONTO, Oct. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE:AIAI) (OTCQB:AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the appointment of P.J. Haley, Executive Vice President, Commercial at Exelixis, Inc. (NASDAQ:EXEL), as a director of the Company, effective October 15th, 2024. Mr. Haley will be replacing Sheetal Jaitly, who is stepping down as a director after a period of dedicated service and contributions to the Company. As NetraMark focuses on advancing its technology for late phas

      10/9/24 8:30:00 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

      – Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 – – Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million; 2024 R&D expense guidance of $925 million - $975 million – – Appointment of two new board members, Mary C. Beckerle, Ph.D., and Gail Eckhardt, M.D., with extensive drug development and corporate governance expertise – – Implementing corporate restructuring to focus R&D resources on clinical stage and IND-enabling activities to maximize pipeline success and operational efficiency – – Board of Directors authorized $450 million share repurchase in 2024 after successful completi

      1/7/24 4:00:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

      -- Dr. Peterson's extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios -- Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Peterson is a veteran oncology drug development leader whose experience includes senior clinical development and operational roles at Genentech, Medivation, BeiGene and CytomX. She joins Exelixis as the company accelerates development of its product pipeline and builds on the success of its global cabozantinib oncology franchise. "With a

      8/23/23 4:30:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

      SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

      5/8/24 4:11:20 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Exelixis Inc.

      SC 13G - EXELIXIS, INC. (0000939767) (Subject)

      2/13/24 9:19:48 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

      SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

      6/2/23 5:05:24 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Financials

    Live finance-specific insights

    See more
    • Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

      - Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 million - - GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of $0.62 - - Increasing 2025 Full Year Net Product Revenues and Total Revenues Guidance by $100 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX® d

      5/13/25 4:07:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

      – Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event

      4/29/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

      - Total Revenues of $567 million for the Fourth Quarter of 2024, $2.17 billion for the Fiscal Year 2024 - - Cabozantinib Franchise Achieved $1.81 billion in U.S. Net Product Revenues for the Fiscal Year 2024, including $515 million for the Fourth Quarter of 2024 - - GAAP Diluted EPS of $0.48 for the Fourth Quarter of 2024, $1.76 for the Fiscal Year 2024 - - Non-GAAP Diluted EPS of $0.55 for the Fourth Quarter of 2024, $2.00 for the Fiscal Year 2024 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectiv

      2/11/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

      – Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% – – Additional results from dose-finding cohorts will also be presented – Exelixis, Inc. (NASDAQ:EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo®) or a fixed-dose combination of nivolumab and relatlimab (Opdualag™) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These findings, as well as data from multiple dose-escalation cohorts from STELLAR-002, will be presented at the 2025 American Society of Clinical Oncology

      5/22/25 5:17:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

      - Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Exelixis is scheduled to present virtually at 2:30 p.m. ET / 11:30 a.m. PT on Tuesday, May 27. William Blair 45th Annual Growth Stock Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 10:00 a.m. CT / 8:00 a.m. PT on Tuesday, June 3 in Chicago. Jefferies Global Healthcare Conference 2025: Exelixis is scheduled to present at 7:35 a.m. ET / 4:35 a.m. PT on Wednesday, June 4 in New York City.

      5/22/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

      Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ:EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1). The molecule was discovered in part through a collaboration between Exelixis and Invenra. About Invenra Inc. Invenra Inc. pioneers the discove

      5/13/25 6:06:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Commercial Haley Patrick J. sold $1,515,091 worth of shares (34,387 units at $44.06), decreasing direct ownership by 8% to 412,072 units (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/22/25 7:25:20 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Heyman Tomas J. sold $201,254 worth of shares (4,544 units at $44.29), decreasing direct ownership by 12% to 32,470 units (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/22/25 7:25:09 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Poste George exercised 20,634 shares at a strike of $19.77 and sold $948,958 worth of shares (20,634 units at $45.99) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/16/25 8:58:27 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling

      9/21/23 4:37:02 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

      7/15/22 4:38:40 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

      9/20/21 3:53:29 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care